Consun Pharmaceutical reports robust interim revenue and profit growth

Consun Pharmaceutical Group Limited reported a substantial 23.7% increase in revenue to RMB1,568,588,000 for the six months ended June 30, 2025. Profit attributable to equity shareholders also rose by 24.6% to RMB498,299,000. Basic earnings per share increased to RMB0.59 from RMB0.50, an 18.0% rise.

The company's gross profit grew by 27.6% to RMB1,208,681,000, with the average gross profit margin improving by 2.4 percentage points to 77.1%. This was primarily attributed to increased sales and lower procurement prices for Chinese medicine raw materials. Distribution costs saw a 25.2% increase to RMB515,650,000 due to expanded marketing and OTC brand building efforts.

Kidney medicines recorded a 28.0% sales increase, maintaining market leadership. Gynaecology and paediatrics medicines became the second-largest revenue contributor, with sales rising by 17.5%. Medical contrast medium sales grew by 22.0%, while dermatologic medicines increased by 19.7%. The group’s net cash generated from operating activities improved by 40.6% to RMB492,695,000.